Access to Study Data. Subject to the provisions of Sections 5.1, and the Pharmacovigilance Agreement, each Party shall have access to all Study Data (including, but not limited to, de-identified patient records) as soon as such Study Data is available to or generated by the Party responsible for generating or collecting such Study Data.
Appears in 2 contracts
Samples: Clinical Trial Collaboration Agreement, Clinical Trial Collaboration Agreement (Exelixis, Inc.)
Access to Study Data. Subject to the provisions of Sections 5.12.2, 5.1(a)(xvi) and 5.1(a)(xvii) and the Pharmacovigilance Agreement, each Party shall have access to all Study Data (including, but not limited to, including de-identified patient records) as soon as promptly after such Study Data is available to or generated by the Party responsible for generating or collecting such Study Data.
Appears in 1 contract
Samples: Clinical Trial Collaboration Agreement (Five Prime Therapeutics Inc)
Access to Study Data. Subject to the provisions of Sections 5.1, and the Pharmacovigilance Agreement, each Party shall have access to all Study Data (including, but not limited to, de-identified patient records) as soon as such reasonably practicable after Study Data is available to or generated by the Party responsible for generating or collecting such Study Data.
Appears in 1 contract
